Tags

Type your tag names separated by a space and hit enter

Dopaminergic Neuroprotection with Atremorine in Parkinson´s Disease.
Curr Med Chem. 2018; 25(39):5372-5388.CM

Abstract

Patients with Parkinson's disease (PD) are looking forward to new therapeutic strategies that may gradually decelerate the rate of neurodegenerative decline, associated with mobility restrictions and related morbidity. Its continuous neurodegenerative process, exacerbated by genetic mutations or environmental toxins, involves a progressive reduction in the dopamine neurotransmission levels, synaptic uptake density, oxidative glucose intake, deficient striatal lactate accumulation and chronic inflammation. Over the last decade, novel bioproducts have received considerable interest due to their unique potential of unifying nutritional, safety and therapeutic natural effects. Some nutraceuticals play a crucial role in the control of the signaling transduction pathways in neurotransmission and inflammation affected in PD, and some natural compounds can beneficially interact with each one of these biological mechanisms to slow down disease progression. Atremorine, a novel plant-derived nutraceutical, probably with a neuroprotective effect in the dopaminergic neurons of the substantia nigra (pars compacta), is a prototype of this new category of bioproducts with potential effects in PD. The major focus of this review will be on the current knowledge and biomedical investigation strategies through a plant-derived neuroprotective approach to improve life quality in PD patients, being of paramount importance for health providers, caregivers and the patients themselves.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Carrera I
Health Biotechnology, EuroEspes Biotechnology, Corunna, Spain. Sechenov First Moscow State Medical University, 119991, Moscow, Russian Federation.
Fernandez-Novoa L
Health Biotechnology, EuroEspes Biotechnology, Corunna, Spain.
Sampedro C
Health Biotechnology, EuroEspes Biotechnology, Corunna, Spain.
Tarasov VV
Sechenov First Moscow State Medical University, 119991, Moscow, Russian Federation.
Aliev G
Gally International Biomedical Research LLC, San Antonio, Texas, United States. University of Atlanta, John Greek , GA, United States. Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation.
Cacabelos R
EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, Corunna, Spain.

MeSH

AnimalsCurcuminDopaminergic NeuronsGinsenosidesHumansLevodopaNeuroprotective AgentsParkinson DiseaseResveratrolVicia faba

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29637853

Citation

Carrera, Ivan, et al. "Dopaminergic Neuroprotection With Atremorine in Parkinson´s Disease." Current Medicinal Chemistry, vol. 25, no. 39, 2018, pp. 5372-5388.
Carrera I, Fernandez-Novoa L, Sampedro C, et al. Dopaminergic Neuroprotection with Atremorine in Parkinson´s Disease. Curr Med Chem. 2018;25(39):5372-5388.
Carrera, I., Fernandez-Novoa, L., Sampedro, C., Tarasov, V. V., Aliev, G., & Cacabelos, R. (2018). Dopaminergic Neuroprotection with Atremorine in Parkinson´s Disease. Current Medicinal Chemistry, 25(39), 5372-5388. https://doi.org/10.2174/0929867325666180410100559
Carrera I, et al. Dopaminergic Neuroprotection With Atremorine in Parkinson´s Disease. Curr Med Chem. 2018;25(39):5372-5388. PubMed PMID: 29637853.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dopaminergic Neuroprotection with Atremorine in Parkinson´s Disease. AU - Carrera,Ivan, AU - Fernandez-Novoa,Lucia, AU - Sampedro,Carolina, AU - Tarasov,Vadim V, AU - Aliev,Gjumrakch, AU - Cacabelos,Ramon, PY - 2016/04/11/received PY - 2017/10/02/revised PY - 2018/02/24/accepted PY - 2018/4/12/pubmed PY - 2019/2/2/medline PY - 2018/4/12/entrez KW - PD animal models KW - Parkinson's disease KW - atremorine KW - biotherapy KW - dopamine agonist KW - neuropathology. SP - 5372 EP - 5388 JF - Current medicinal chemistry JO - Curr Med Chem VL - 25 IS - 39 N2 - Patients with Parkinson's disease (PD) are looking forward to new therapeutic strategies that may gradually decelerate the rate of neurodegenerative decline, associated with mobility restrictions and related morbidity. Its continuous neurodegenerative process, exacerbated by genetic mutations or environmental toxins, involves a progressive reduction in the dopamine neurotransmission levels, synaptic uptake density, oxidative glucose intake, deficient striatal lactate accumulation and chronic inflammation. Over the last decade, novel bioproducts have received considerable interest due to their unique potential of unifying nutritional, safety and therapeutic natural effects. Some nutraceuticals play a crucial role in the control of the signaling transduction pathways in neurotransmission and inflammation affected in PD, and some natural compounds can beneficially interact with each one of these biological mechanisms to slow down disease progression. Atremorine, a novel plant-derived nutraceutical, probably with a neuroprotective effect in the dopaminergic neurons of the substantia nigra (pars compacta), is a prototype of this new category of bioproducts with potential effects in PD. The major focus of this review will be on the current knowledge and biomedical investigation strategies through a plant-derived neuroprotective approach to improve life quality in PD patients, being of paramount importance for health providers, caregivers and the patients themselves. SN - 1875-533X UR - https://www.unboundmedicine.com/medline/citation/29637853/Dopaminergic_Neuroprotection_with_Atremorine_in_Parkinson´s_Disease_ DB - PRIME DP - Unbound Medicine ER -